S L Heltshe1, U Khan2, V Beckett2, A Baines2, J Emerson3, D B Sanders4, R L Gibson3, W Morgan5, M Rosenfeld3. 1. CFF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA 98105, USA; Division of Pediatric Pulmonology, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98121, USA. Electronic address: sonya.heltshe@seattlechildrens.org. 2. CFF Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA 98105, USA. 3. Division of Pediatric Pulmonology, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA 98121, USA. 4. Department of Pediatrics, Riley Hospital for Children, School of Medicine, Indiana University, Indiana, IN 46202, USA. 5. Department of Pediatrics, University of Arizona, Tucson, AZ, USA.
Abstract
BACKGROUND: While the emergence of chronic and mucoid Pseudomonas aeruginosa (Pa) infection are both associated with poorer outcomes among CF patients, their relationship is poorly understood. We examined the longitudinal relationship of incident, chronic and mucoid Pa in a contemporary, young CF cohort in the current era of Pa eradication therapy. METHODS: This retrospective cohort was comprised of patients in the U.S. CF Foundation Patient Registry born 2006-2015, diagnosed before age 2, and with at least 3 respiratory cultures annually. Incidence and age-specific prevalence of Pa infection stages (initial and chronic [≥ 3Pa+cultures in prior year]) and of mucoid Pa were summarized. Transition times and the interaction between Pa stage and acquisition of mucoid Pa were examined via Cox models. RESULTS: Among the 5592 CF patients in the cohort followed to a mean age of 5.5years, 64% (n=3580) acquired Pa. Of those, 13% (n=455) developed chronic Pa and 17% (n=594) cultured mucoid Pa. Among those with mucoid Pa, 36% (211/594) had it on their first recorded Pa+culture, while mucoid Pa emerged at or after entering the chronic stage in 12% (73/594). Mucoidy was associated with significantly increased risk of transition to chronic Pa infection (HR=2.59, 95% CI 2.11, 3.19). CONCLUSIONS: Two-thirds of early-diagnosed young children with CF acquired Pa during a median 5.6years of follow up, among whom 13% developed chronic Pa and 17% acquired mucoid Pa. Contrary to our hypothesis, 87% of young children who developed mucoid Pa did so before becoming chronically infected.
BACKGROUND: While the emergence of chronic and mucoid Pseudomonasaeruginosa (Pa) infection are both associated with poorer outcomes among CF patients, their relationship is poorly understood. We examined the longitudinal relationship of incident, chronic and mucoid Pa in a contemporary, young CF cohort in the current era of Pa eradication therapy. METHODS: This retrospective cohort was comprised of patients in the U.S. CF Foundation Patient Registry born 2006-2015, diagnosed before age 2, and with at least 3 respiratory cultures annually. Incidence and age-specific prevalence of Pa infection stages (initial and chronic [≥ 3Pa+cultures in prior year]) and of mucoid Pa were summarized. Transition times and the interaction between Pa stage and acquisition of mucoid Pa were examined via Cox models. RESULTS: Among the 5592 CF patients in the cohort followed to a mean age of 5.5years, 64% (n=3580) acquired Pa. Of those, 13% (n=455) developed chronic Pa and 17% (n=594) cultured mucoid Pa. Among those with mucoid Pa, 36% (211/594) had it on their first recorded Pa+culture, while mucoid Pa emerged at or after entering the chronic stage in 12% (73/594). Mucoidy was associated with significantly increased risk of transition to chronic Pa infection (HR=2.59, 95% CI 2.11, 3.19). CONCLUSIONS: Two-thirds of early-diagnosed young children with CF acquired Pa during a median 5.6years of follow up, among whom 13% developed chronic Pa and 17% acquired mucoid Pa. Contrary to our hypothesis, 87% of young children who developed mucoid Pa did so before becoming chronically infected.
Authors: Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson Journal: J Pediatr Date: 2007-06-22 Impact factor: 4.406
Authors: Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard Journal: JAMA Date: 2005-02-02 Impact factor: 56.272
Authors: M Proesmans; W Balinska-Miskiewicz; L Dupont; X Bossuyt; J Verhaegen; N Høiby; K de Boeck Journal: Eur Respir J Date: 2006-05 Impact factor: 16.671
Authors: Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey Journal: Arch Pediatr Adolesc Med Date: 2011-09
Authors: Hara Levy; Leslie A Kalish; Carolyn L Cannon; K Christopher García; Craig Gerard; Don Goldmann; Gerald B Pier; Scott T Weiss; A A Colin Journal: Pediatr Pulmonol Date: 2008-05
Authors: Edith T Zemanick; Julia Emerson; Valeria Thompson; Sharon McNamara; Wayne Morgan; Ronald L Gibson; Margaret Rosenfeld Journal: Pediatr Pulmonol Date: 2014-03-18
Authors: Catherine R Armbruster; Christopher W Marshall; Arkadiy I Garber; Jeffrey A Melvin; Anna C Zemke; John Moore; Paula F Zamora; Kelvin Li; Ian L Fritz; Christopher D Manko; Madison L Weaver; Jordan R Gaston; Alison Morris; Barbara Methé; William H DePas; Stella E Lee; Vaughn S Cooper; Jennifer M Bomberger Journal: Cell Rep Date: 2021-10-19 Impact factor: 9.423
Authors: Melissa S Phuong; Rafael E Hernandez; Daniel J Wolter; Lucas R Hoffman; Subash Sad Journal: Cell Death Dis Date: 2021-03-04 Impact factor: 8.469
Authors: Jonathan D Cogen; Anna V Faino; Frankline Onchiri; Lucas R Hoffman; Matthew P Kronman; David P Nichols; Margaret Rosenfeld; Ronald L Gibson Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 20.999